• Cefdinir packaged and labeled.

click on thumbnail to zoom
SKU: C049

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

Cefdinir is a broad-spectrum, third-generation cephalosporin resistant to many β-lactamase enzymes.  It is structurally similar to Cefixime.  It was patented in 1979 by Fujisawa Pharmaceutical.  It has been found to be involved in inflammation, as an inhibitor of neutrophil myeloperoxidases.  Cedinir is highly soluble in aqueous solution.

    CAS Number

    91832-40-5

    Molecular Formula

    C14H13N5O5S2

    Molecular Weight

    395.42

    Mechanism of Action

    Cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases, however, Cefdinir is not typically inactivated by this mechanism.

    Cefdinir is an inhibitor of neutrophil myeloperoxidases.  It can also interact with the dipeptide transporters PEPT1 and PEPT2.  

    Storage Conditions

    -20°C

    Tariff Code

    2941.90.5000

    Spectrum

    Cefdinir targets both Gram-positive and Gram-negative bacteria, including those responsible for ear, sinus and skin infections.

Applications

    Eukaryotic Cell Culture Applications

    Cefdinir Inhibits the luminol-amplified chemiluminescence (LACL) response of human neutrophils stimulated by PMA (but not opsonized zymosan) in a concentration-dependent manner.  Cefdinir also inhibited LACL generation in cell-free systems consisting of H2O2, NaI, and either horseradish peroxidase or a myeloperoxidase-containing neutrophil extract (Labro et al, 1994).

    Cefdinir inhibits the activity of myeloperoxidase-containing neutrophil extract released into the extracellular medium during neutrophil stimulation by soluble mediators, but has no effect on that released into the phagolysosome during phagocytosis. This unusual property could be of interest in modulating the exaggerated inflammatory process associated with infectious diseases. (Labro et al, 1994).

    Microbiology Applications

    Cefdinir is commonly used in clinical in vitromicrobiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options .  Representative MIC values include:

    • Haemophilus influenzae 0.05 µg/mL – 3.13 µg/mL
    • Staphylococcus aureus 0.125 µg/mL - >128 µg/mL
    • For a representative list of Cefdinir MIC values, click here.

Specifications

    Form

    Powder

    Appearance

    White or light yellow powder

    Source

    Synthetic

    Water Content (Karl Fischer)

    ≤3.0%

    Optical Rotation

    -67° to -61°

    Assay

    (On Dried Basis): 960-1020 µg/mg

    Residue On Ignition

    ≤0.2%

    Impurities

    Impurity G: ≤0.7%
    Single Impurity: ≤0.2%
    Total Impurities: ≤3.0%

References

    References

    Reference for TOKU-E product:

    Kaul M et al (2016)  Combining the FtsZ-targeting prodrug TXA709 and the cephalosporin Cefdinir confers synergy and reduces the frequency of resistance in Methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 60(7):4290-4296 Link to article

    Other References:

    Georgopapadakou NH (1992)  Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob. Agents Chemother.  37(3):559-565

    Inamoto, Y et al (1988)  FK 482, a new orally active cephalosporin synthesis and biological properties. J. Antibiotic. 41(6):828-830 PMID 3255303

Other Items In This Category